In partnership with management, Arlington strengthened Stellant’s storied heritage through major investments in manufacturing infrastructure, new product developmentIn partnership with management, Arlington strengthened Stellant’s storied heritage through major investments in manufacturing infrastructure, new product development

Arlington Capital Partners to Sell Stellant Systems, Inc to TransDigm Group for $960 Million

In partnership with management, Arlington strengthened Stellant’s storied heritage through major investments in manufacturing infrastructure, new product development and human capital

WASHINGTON–(BUSINESS WIRE)–Arlington Capital Partners, a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced it has agreed to sell Stellant Systems, Inc (“Stellant” or “the Company”), a premier designer and manufacturer of radio frequency (“RF”) and microwave amplification products, to TransDigm Group Incorporated (“TransDigm Group”) (NYSE: TDG), a leading global designer, producer and supplier of highly engineered aircraft components, for $960 million.

Headquartered in Torrance, CA, Stellant designs and manufactures vacuum electron devices, solid state power amplifiers and related RF components for the defense, space, medical and industrial markets. The Company supports critical space, radar, missile and secure communications platforms for the Department of War and allied militaries globally. Stellant operates across four U.S. facilities, totaling more than 700,000 square feet of advanced manufacturing space, and employs approximately 950 people.

Peter Manos, a Managing Partner at Arlington Capital Partners, said: “Stellant is another example of an IP-rich strategic carve out creating an Arlington platform company where organic and inorganic investment in people, research and development, product expansion and manufacturing capability and capacity has created a highly sought-after asset. It has been a remarkable journey working alongside Keith and the broader Stellant management team as we scaled an important manufacturer with what we hope will be a multi-generation legacy. TransDigm Group is the perfect long-term home for Stellant, and its interest in partnering with the Company is a testament to Stellant’s strength and its role as a valued partner to its customers.”

“I am incredibly proud of what Stellant has been able to accomplish for its customers and the broader defense ecosystem,” said Keith Barclay, CEO of Stellant Systems. “With significant improvements in operational efficiency and an exciting pipeline of new products, Stellant has never been stronger than it is today. On behalf of the entire Stellant team, I am sincerely grateful for Arlington’s partnership, and we are confident that TransDigm Group is the right partner for our next phase of growth.”

Ben Ramundo, a Managing Director at Arlington Capital Partners, added: “Throughout the course of Arlington’s stewardship, Stellant significantly improved on-time delivery and created an employee-centric culture with an added focus on high-quality customer outcomes. Our investment in Stellant is consistent with Arlington’s long-term, growth-oriented philosophy and deepens our expertise in defense electronics and related technologies, where we see a significant opportunity to build industry-leading platforms that deliver innovation and solve supply chain bottlenecks for the national security community.”

Harris Williams served as exclusive financial advisor and Kirkland & Ellis served as legal counsel to Arlington and Stellant during the transaction.

The transaction is expected to close in 2026, subject to customary regulatory approvals and closing conditions.

About Stellant Systems, Inc.

Stellant Systems is a premier manufacturer of critical spectrum RF/Microwave power amplification products to the space, defense, medical, science, and industrial markets for both domestic and international customers. Stellant has four domestic manufacturing facilities and approximately 950 employees.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. Focused on the aerospace and defense, government services and technology, and healthcare sectors, the Firm partners with founders and entrepreneurs to build platforms of strategic importance to national priorities. Operating in markets with high barriers to entry, Arlington looks to partner with organizations within these industries that save lives, improve effectiveness, and reduce costs. Since inception in 1999, Arlington has invested in approximately 200 companies and raised over $14 billion in committed capital. For more information, visit Arlington’s website at http://www.arlingtoncap.com and follow Arlington on LinkedIn.

Contacts

Media Contacts
Arlington Capital Partners

Ryan FitzGibbon

Pro-arlington@prosek.com

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$0.5472
$0.5472$0.5472
+1.22%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Media & Crypto.com Partner For Shareholder Token Airdrop

Trump Media & Crypto.com Partner For Shareholder Token Airdrop

Trump Media & Technology Group (NASDAQ:DJT) has announced plans to distribute a new digital token to its shareholders, leveraging Crypto.com‘s infraread more
Share
Coinstats2026/01/01 00:23
Tria’s $20m beta surge: How a self-custodial neobank is redefining onchain finance

Tria’s $20m beta surge: How a self-custodial neobank is redefining onchain finance

CEO Vijit Katta shares with crypto.news how Tria is reshaping digital asset banking and paving the way for a frictionless, user-controlled financial future.
Share
Crypto.news2026/01/01 01:00
The FDA Is Trying To Make Corporate Free Speech Situational

The FDA Is Trying To Make Corporate Free Speech Situational

The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…
Share
BitcoinEthereumNews2025/09/18 06:29